News and Trends 30 Nov 2016 FDA and EMA review the First Therapy for a Deadly Skin Cancer Merck and Pfizer have been granted priority review by the FDA for the first treatment dealing with one of the most aggressive forms of skin cancer. The FDA has accepted Merck and Pfizer‘s market application for avelumab in metastatic Merkel cell carcinoma (MCC) with priority review. Just a month ago, the EMA also accepted their application. If […] November 30, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Nov 2016 UPDATE: GSK is staging a comeback with a new Shingles Vaccine GSK is banishing concerns about its health with a BLA submission for Shingrix, which has outperformed Merck’s standard and could bring GSK close to €1Bn. London-based GSK has just submitted a Biologics License Application to the FDA for its shingles vaccine candidate, Shingrix. Though it is still experimental, the vaccine is proving itself superior to the […] November 30, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 30 Nov 2016 Drugging the Undruggable: New Acquisition to Boost GPCR Drugs Heptares Therapeutics has acquired G7 Therapeutics to take control over its GPCR technology, boost its pipeline and keep competitors in this profitable field at bay. Heptares Therapeutics develops therapies directed to G protein-coupled receptors (GPCRs), a large family of hot but elusive targets for biopharma. The British company, owned by the Japanese Sosei, just announced it […] November 30, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Nov 2016 This was Labiotech Refresh! Check our recap and highlight video! Six months have passed since the last time we opened the doors for the very first Labiotech Refresh, Europe’s most refreshing Biotech Conference. Last week we launched our second edition live from Le Machine du Moulin Rouge in Paris! Were you not able to attend? Don’t worry! Here is our highlight video: And here’s also a […] November 30, 2016 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 Nov 2016 Treating the Inner Ear: a solution for Vertigo is on the way! Sensorion is about to start Phase II trials to treat acute severe vertigo. What makes the inner ear such an attractive target for biotech? Sensorion is a French biotech developing treatments for inner ear pathologies, including vertigo, tinnitus and hearing loss. The company has just announced the start of Phase II trials with SENS-111, a drug candidate […] November 29, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 Nov 2016 One Step Closer to the First Triple Combination Therapy for Cystic Fibrosis Galapagos and AbbVie are closer to launching a cystic fibrosis treatment that can outperform the current standards. However, gene therapy and CRISPR might end up taking over in the long term. Despite being abandoned by AbbVie in its rheumatoid arthritis program, Galapagos and the big US pharma expanded their cystic fibrosis partnership in May. The […] November 29, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 Nov 2016 New British Partnership set to Cure Rare Diseases with Gene Therapy Oxford BioMedica and Orchard Therapeutics are partnering up to bring gene therapy to the market and treat rare diseases for which no cure is available yet. Oxford BioMedica develops lentiviral vectors for gene and cell therapy applications. The company just announced a partnership with another biotech from the UK’s golden triangle, Orchard Therapeutics. The deal is […] November 29, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 29 Nov 2016 The ABCs of ADCs: A Review of Antibody Drug Conjugates Antibody therapies have a little sister who is catching up in funding – and hype? In light of now five deaths from Juno’s CAR-T therapy, antibody drug conjugates are attracting a lot of interest in a resurgence after their debut 10 years ago. To feel out the field, we talked to two CEOs competing directly […] November 29, 2016 - 8 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 28 Nov 2016 Finally a Cure for the Common Cold? And it’s Needle-free! Mucosis is starting Phase I trials for SynGEM, a needle-free vaccine against RSV, which causes 200k deaths per year and has a huge cost for both healthcare and the economy. Mucosis is a biotech from the Netherlands developing needle-free vaccines. The company has now initiated the first human trial for SynGEM, a nasal spray vaccine against […] November 28, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Nov 2016 SynBio reinvents Photosynthesis with artificial CO2-fixing Pathway Removing CO2 from the atmosphere could help with climate change, and there’s now a new biological method in the making to achieve this. Researchers have developed a new turbo-charged version of a metabolic pathway for fixing CO2, which is 20% more efficient than in plants. As described in an article just published in Science, a […] November 28, 2016 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
Interview 28 Nov 2016 Needle-Free Diabetes Monitoring: Interview with the Co-Founder of GlucoWise The needle-free revolution for diabetes is coming! We interviewed Panos Kosmas, co-founder of MediWise, to get the juicy details of GlucoWise. This revolutionary wireless device could free the more than 422 million people living with diabetes worldwide from the daily pain of conventional glucose monitoring. Panos Kosmas is the co-founder and Chief Technical Officer of MediWise, a […] November 28, 2016 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 26 Nov 2016 Fruit Flies are the Artists behind these Astounding Exhibitions The Fly Printer by Laura Beloff transforms fruit flies into artists behind pieces that highlight the limits of always making humans the point of reference in technology. Fruit flies are a very common model organism for experimentation in biotech. Now, a piece of art at the Open Fields exhibition in Riga is inverting the roles […] November 26, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email